| Disease | Tissue/ Cell line | MicroRNA regulation | Targeted Member | Pathway | More Details | References |
|---|---|---|---|---|---|---|
| Non-small cell lung cancer | Lung | Down | ABL1 | ERK pathway | MicroRNA-3127 expression levels are associated with dasatinib sensitivity in non-small cell lung cancer through the c-Abl/Ras/ERK pathway. | Sun et al., 2014 |
| Hepatocellular carcinoma | Hepatocyte | Up | PHLPP2 | PI3K-Akt signaling pathway | PHLPP1 and PHLPP2 are the direct target of hsa-miR-3127. hsa-miR-3127 inhibits HCC cell proliferation and tumor growth by suppressing the PI3K-Akt signaling pathway. | Jiang et al., 2015 |
| Hepatocellular carcinoma | Hepatocyte | Up | INPP4A | PI3K-Akt signaling pathway | INPP4A is the direct target of hsa-miR-3127. hsa-miR-3127 inhibits HCC cell proliferation and tumor growth by suppressing the PI3K-Akt signaling pathway. | Jiang et al., 2015 |
| Hepatocellular carcinoma | Hepatocyte | Up | INPP5J | PI3K-Akt signaling pathway | INPP5J is the direct target of hsa-miR-3127. hsa-miR-3127 inhibits HCC cell proliferation and tumor growth by suppressing the PI3K-Akt signaling pathway. | Jiang et al., 2015 |